Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunologic therapy for relapsing-remitting multiple sclerosis.

H J MacLean1, M S Freedman

  • 1Multiple Sclerosis Clinic, University of Ottawa, Ottawa Hospital-General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada.

Current Neurology and Neuroscience Reports
|March 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2021
Same author

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis and related disorders·2020
Same author

The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.

Current medical research and opinion·2019
Same author

Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents.

AJNR. American journal of neuroradiology·2018
Same author

Laboratory maintenance does not alter ecological and physiological patterns among species: a Drosophila case study.

Journal of evolutionary biology·2018
Same author

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2017
Same journal

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026
Same journal

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026
Same journal

Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.

Current neurology and neuroscience reports·2026
Same journal

Astrocytopathy in Wernicke Encephalopathy and Neuromyelitis Optica Spectrum Disorder. Pathogenic Differences With Occasional Clinical and Neuroimaging Overlap. A Review.

Current neurology and neuroscience reports·2026
Same journal

When is the Radiologically Isolated Syndrome already Multiple Sclerosis According to the 2024 McDonald Criteria?

Current neurology and neuroscience reports·2026
Same journal

Assessment and Management of Post-traumatic Headache.

Current neurology and neuroscience reports·2026
See all related articles

New therapies for relapsing-remitting multiple sclerosis (RRMS) effectively treat relapses and may slow disease progression. Early intervention with these disease-modifying treatments is recommended for better long-term outcomes in managing MS.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Therapeutics

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) is the most prevalent form of MS.
  • Recent advancements have transformed RRMS management.
  • Current therapies address acute relapses and disease modification.

Purpose of the Study:

  • To discuss the current treatment landscape for RRMS.
  • To highlight the evolution of therapeutic strategies.
  • To emphasize the importance of early intervention.

Main Methods:

  • Review of recent clinical studies and therapeutic approvals for RRMS.
  • Analysis of the impact of disease-modifying therapies on disease course.
  • Discussion of magnetic resonance imaging (MRI) as a measure of disease burden.

Related Experiment Videos

Main Results:

  • Multiple therapeutic agents are available or in development for RRMS.
  • These treatments can prevent relapses and reduce MRI-detected disease burden.
  • Evidence supports that early treatment initiation leads to superior long-term outcomes.

Conclusions:

  • The treatment paradigm for RRMS has significantly advanced.
  • Early intervention with disease-modifying therapies is crucial for optimal patient outcomes.
  • Ongoing research and development continue to improve RRMS management strategies.